Skip to content
Menu

NeuroSense Therapeutics Ltd. NRSN

Full chart Compare
Set alert

Price alert · NRSN

All alert types
1.69 USD -0.07 (-3.98%)

Regular-session close

1.71 +0.02 +1.18%

After hours · Nov 13, 4:00 PM ET

1.60 Day range 1.78
1.10 52-week range 25.40
YTD
-89.01%
1 year
-90.80%
Market cap
3.21M
EPS (ttm)
-47.10
Shares out
23.13M
Forward P/E
-2.27
YTD return
-89.01%
1-year return
-90.80%
Volume
18.16K
Avg volume
32.59K
Open
1.77
Previous close
1.76
Day's range
1.60 – 1.78
52-week range
1.10 – 25.40
Beta
1.56
Analysts
Buy
Price target
7.50 (+343.8%)

5D +0.61 (+44.53%)

1.401.601.802WedThuFriMonTue1.98

Key statistics

Enterprise value
19.41M
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-6.63M
Total cash
1.21M
Total debt
36.00K
Return on equity
0.00%
Short % of float
1.84%
50-day average
1.13
200-day average
1.16

Fundamental scorecard

5 of 25 checks passed on NRSN’s reported financials

Value: 0/5ValueGrowth: 1/5GrowthProfitability: 0/5ProfitabilityFinancial health: 4/5HealthDividend: 0/5Dividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
NRSN Revenue — quarterly 0
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024
NRSN Net income — quarterly -1.80M
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024
NRSN EPS — quarterly -1.20
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024

Earnings

NRSN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 18, 2024Sep 1, 20240.00-0.11——
Jun 24, 2024Mar 1, 20240.00-0.35——
Apr 5, 2024Dec 1, 20230.00-0.16——
Nov 28, 2023Sep 1, 20230.000.10——
Aug 16, 2023Jun 1, 20230.00-0.44——
Jun 1, 2023Mar 1, 20230.00-0.33——

Upgrades / downgrades

NRSN analyst upgrades and downgrades
DateFirmActionFromTo
Dec 16, 2024Maxim GroupdownBuyHold

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel

News

Your note

Sign in to keep a note on NRSN — it syncs with the Stock Master app.

Institution ownership

NRSN institution ownership
Holder% heldSharesValueReported
Cantor Fitzgerald, L.P.0.34%79,49299.36KSep 29, 2024
Xtx Topco Ltd0.20%45,99657.49KSep 29, 2024
Meitav Investment House Ltd.0.17%40,00050.00KSep 29, 2024
Citadel Advisors Llc0.15%34,28042.85KSep 29, 2024
Commonwealth Equity Services, LLC0.05%12,62515.78KSep 29, 2024
Geode Capital Management, LLC0.05%11,96314.95KSep 29, 2024

Fund ownership

NRSN fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.05%11,96314.95KOct 30, 2024